Wu Aodi, Zhang Yuting, Liu Caidong, Zhumanov Kaiat, He Tao, Yan Kexin, Li Honghuan, Fu Shuangshaung, Li Xin, Zhang Wenxiang, Meng Chuang, Zhang Changsuo, Sheng Jinliang, Ma Zhongchen, Xu Mingguo, Zhang Junbo, Yi Jihai, Wang Yueli
College of Animal Science and Technology, Shihezi University, Shihezi, 832003, Xinjiang, China.
School of Medicine, Shihezi University, Shihezi, 832003, Xinjiang, China.
Microb Cell Fact. 2025 Apr 15;24(1):84. doi: 10.1186/s12934-025-02713-0.
Brucellosis is one of the most common zoonotic diseases caused by Brucella spp. However, there is currently no Brucella vaccine available for humans. Although some attenuated live vaccines have been approved for animals, their protective efficacy is suboptimal. In previous studies, we utilized an epitope- and structure-based vaccinology platform to identify the immunodominant epitopes of Brucella antigens OMP19, OMP16, OMP25, and L7/L12, and constructed the multi-epitope vaccine MEV-Fc against Brucella. In this study, OMP19, OMP16, OMP25, and L7/L12, and MEV-Fc was expressed and purified via an Escherichia coli expression system, which validated that MEV-Fc possesses high immunological efficacy and exerts a significant protective effect in BALB/c mice within the Brucella infection model. MEV-Fc enhanced Th1 and Th2 immune responses and strongly induced the production of the pro-inflammatory cytokine IFN-γ. Furthermore, MEV-Fc protected mice against Brucella infection compared to control group (PBS). In conclusion, our results provide new insights and data support for the development of human Brucella vaccines.
布鲁氏菌病是由布鲁氏菌属引起的最常见的人畜共患病之一。然而，目前尚无用于人类的布鲁氏菌疫苗。尽管一些减毒活疫苗已被批准用于动物，但其保护效果并不理想。在先前的研究中，我们利用基于表位和结构的疫苗学平台鉴定了布鲁氏菌抗原OMP19、OMP16、OMP25和L7/L12的免疫显性表位，并构建了抗布鲁氏菌的多表位疫苗MEV-Fc。在本研究中，通过大肠杆菌表达系统表达并纯化了OMP19、OMP16、OMP25、L7/L12和MEV-Fc，这证实了MEV-Fc具有高免疫效力，并在布鲁氏菌感染模型中对BALB/c小鼠发挥了显著的保护作用。MEV-Fc增强了Th1和Th2免疫反应，并强烈诱导促炎细胞因子IFN-γ的产生。此外，与对照组（PBS）相比，MEV-Fc保护小鼠免受布鲁氏菌感染。总之，我们的结果为人类布鲁氏菌疫苗的开发提供了新的见解和数据支持。
